

Metastasiertes Nierenzellkarzinom – Standards 2021

Christian Doehn, Susanne Krege

Literatur

1. Salonia A, Bettocchi C, Carvalho J, et al. EAU Guidelines on Sexual and Reproductive Health. European Association of Urology 2020
2. Mulhall JP, Trost LW, Brannigan RE et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol 2018; 200: 423
3. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM 2018
4. S3-AWMF-Leitlinie (Registernummer 043 - 022OL) Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms
5. Bhasin S, Brito JP, Cunningham GR et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010; 95: 2536 – 2559
6. Kacker R, Hult M, San Francisco IF et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016; 18: 16 – 20
7. Snyder PJ, Bhasin S, Cunningham GR et al. Lessons From the Testosterone Trials. Endocrin Rev. 2018; 1;39(3):369 – 386
8. La Vignera S, Calogero AE, Cannarella R et al. Androgens: Clinical Research and Therapeutics Published 2020; 1:1 Online: doi.org/10.1089/andro.2020.0001